Skip to main content

Table 3 Relationship of day 4 (end of infusion) values to 28-day mortality in PROWESS placebo patients

From: Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)

  

Sample size

Univariate odds ratio

Measure

Cut-offa

Higher risk

Lower risk

Odds ratio (95% CI)

P

Protein C (%)

<42

240

578

4.63 (3.35 to 6.41)

<0.0001

Protein S (%)

<42

297

521

3.25 (2.38 to 4.43)

<0.0001

Antithrombin III (%)

<60

306

512

4.17 (3.05 to 5.71)

<0.0001

Interleukin-6 (pg/ml)

≥185.6

264

563

7.27 (5.23 to 10.11)

<0.0001

Prothrombin time (seconds)

≥18.4

233

585

6.13 (4.40 to 8.56)

<0.0001

D-dimer (μg/ml)

≥4.63

408

410

2.13 (1.57 to 2.89)

<0.0001

Cardiovascular SOFA

≥3

301

539

7.32 (5.28 to 10.13)

<0.0001

Respiratory SOFA

≥3

358

482

3.36 (2.48 to 4.56)

<0.0001

Renal SOFA

≥1

335

505

4.82 (3.52 to 6.59)

<0.0001

Hematologic SOFA

≥2

252

588

3.42 (2.50 to 4.68)

<0.0001

Hepatic SOFA

≥1

256

573

2.11 (1.55 to 2.89)

<0.0001

  1. aCut-off was defined by the day 4 (end of infusion) value that resulted in maximum sensitivity and specificity for predicting 28-day mortality. CI, confidence interal; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis; SOFA, Sequential Organ Failure Assessment.